Tumor News and Research

RSS

TGen-led study reveals viable target to prevent spread of brain cancer

A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute.

11 Nov 2013

Breast cancer drug appears to protect cells against UV radiation, inflammation

Exemestane, a synthetic steroid drug widely prescribed to fight breast cancers that thrive on estrogens, not only inhibits the production of the hormone, but also appears to protect cells throughout the body against damage induced by UV radiation, inflammation and other assaults, according to results of research by Johns Hopkins scientists.

8 Nov 2013

Peptide from cow's milk exhibits potent anticancer capability against human stomach cancer cell cultures

New research from a team of researchers in Taiwan indicates that a peptide fragment derived from cow's milk, known as lactoferricin B25 (LFcinB25), exhibited potent anticancer capability against human stomach cancer cell cultures.

8 Nov 2013

New zebrafish technique finds potential treatments for multiple diseases

Skeletal muscle has proved to be very difficult to grow in patients with muscular dystrophy and other disorders that degrade and weaken muscle. Researchers at Boston Children's Hospital's Stem Cell Program now report boosting muscle mass and reversing disease in a mouse model of Duchenne muscular dystrophy, using a "cocktail" of three compounds identified through a new rapid culture system. Adding the same compounds to stem cells derived from patients' skin cells, they then successfully grew human muscle cells in a dish.

8 Nov 2013

Study examines effectiveness of minimally invasive endoscopic procedure for removing esophagus

Use of a minimally invasive endoscopic procedure to remove superficial, early stage esophageal cancer is as effective as surgery that takes out and rebuilds the esophagus, according to a study by researchers at Mayo Clinic in Florida. The research, published in Clinical Gastroenterology and Hepatology, examined national outcomes from endoscopic treatment compared to esophagectomy, surgical removal of the esophagus.

8 Nov 2013

Report: Postmastectomy pain rated as most troubling symptom by breast cancer survivors

More than 40 percent of 200,000 U.S. women diagnosed with breast cancer every year undergo surgery. Though treatment advances have significantly reduced mortality from breast cancer, a study published in The Journal of Pain reported that persistent postmastectomy pain is rated by survivors as their most troubling symptom. The Journal of Pain is published by the American Pain Society, www.americanpainsociety.org.

8 Nov 2013

Cancer research leaders announce the opening of ICGC-TCGA-DREAM SMC Challenge

Cancer research leaders from the Ontario Institute for Cancer Research and the University of California, Santa Cruz, in collaboration with Sage Bionetworks and IBM's DREAM, will announce tomorrow the opening of the ICGC-TCGA-DREAM Somatic Mutation Calling Challenge at the Sixth Annual RECOMB/ISCB conference.

8 Nov 2013

Cancer pioneer James Allison wins 2013 Innovations Award for bioscience

For basic science research that opened a completely new approach for treating cancer, The Economist has named James Allison, Ph.D., professor and chair of Immunology at The University of Texas MD Anderson Cancer Center, as its 2013 Innovations Award winner in Bioscience.

8 Nov 2013

Cholesterol metabolite promotes tumor growth in breast cancers

A team of researchers at UT Southwestern has found that as cholesterol is metabolized, a potent stimulant of breast cancer is created - one that fuels estrogen-receptor positive breast cancers, and that may also defeat a common treatment strategy for those cancers.

8 Nov 2013

EKF Diagnostics to introduce upgraded POC analyzer and new sTNFr1 test kit at Medica 2013

EKF, announces it will be premiering two novel diagnostic tests at Medica 2013, 20th to 23rd November, Düsseldorf, Germany.

From EKF Diagnostics 8 Nov 2013

Researchers identify enzymes that are crucial for growth of cancers with genetic aberrations in p53

The most frequently mutated gene across all types of cancers is a gene called p53. Unfortunately it has been difficult to directly target this gene with drugs. Now a multi-institutional research team, led by Dr. Lewis Cantley and investigators at Weill Cornell Medical College, has identified a family of enzymes they say is crucial for the growth of cancers that have genetic aberrations in p53.

8 Nov 2013

Lactoferricin B25 derived from cow's milk shows promise for treatment of gastric cancer

8 Nov 2013

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, today announced it has secured $9 million in a milestone-based Series A financing from Ally Bridge Group. Previous investments in the Company were converted into Series A preferred stock. ImmunGene will use the capital to advance its early-stage development products to IND-enabling studies.

7 Nov 2013

Investigators find potential new target for treatment of low-grade gliomas

Investigators at Johns Hopkins have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas, potentially offering a new target for the treatment of these cancers.

7 Nov 2013

Researchers discover relationship between TGFb signalling pathways and CXCR4 in HCC

Researchers from the Biological clues of the invasive and metastatic phenotype group of the Bellvitge Biomedical Research Institute (IDIBELL) led by Isabel Fabregat have discovered the relationship between the TGFb signalling pathways and CXCR4 in hepatocellular carcinoma (HCC) .

7 Nov 2013

Parent's use of digital photography shown as effective tool in diagnosis of retinoblastoma

Can parents use digital cameras and smart phones to potentially screen their children for the most common form of pediatric eye cancer? Baylor University and Harvard Medical School researchers believe so.

7 Nov 2013

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

6 Nov 2013

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, today announced the start of clinical testing with its EGFR-targeting ADC, IMGN289.

6 Nov 2013

ImmunoGen decides to stop IMGN901 Phase II SCLC study

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, announced today the decision to stop the IMGN901 Phase II SCLC study, following the recommendation of the trial's independent Data Monitoring Committee.

6 Nov 2013

Study: Interactions between inflammation and changes in gut microbiota may result in colon tumors

Transferring the gut microbes from a mouse with colon tumors to germ-free mice makes those mice prone to getting tumors as well, according to the results of a study published in mBio-, the online open-access journal of the American Society for Microbiology.

6 Nov 2013

Tumor News and Research

TGen-led study reveals viable target to prevent spread of brain cancer

Breast cancer drug appears to protect cells against UV radiation, inflammation

Peptide from cow's milk exhibits potent anticancer capability against human stomach cancer cell cultures

New zebrafish technique finds potential treatments for multiple diseases

Study examines effectiveness of minimally invasive endoscopic procedure for removing esophagus

Report: Postmastectomy pain rated as most troubling symptom by breast cancer survivors

Cancer research leaders announce the opening of ICGC-TCGA-DREAM SMC Challenge

Cancer pioneer James Allison wins 2013 Innovations Award for bioscience

Cholesterol metabolite promotes tumor growth in breast cancers

EKF Diagnostics to introduce upgraded POC analyzer and new sTNFr1 test kit at Medica 2013

Researchers identify enzymes that are crucial for growth of cancers with genetic aberrations in p53

Lactoferricin B25 derived from cow's milk shows promise for treatment of gastric cancer

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

Investigators find potential new target for treatment of low-grade gliomas

Researchers discover relationship between TGFb signalling pathways and CXCR4 in HCC

Parent's use of digital photography shown as effective tool in diagnosis of retinoblastoma

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

ImmunoGen decides to stop IMGN901 Phase II SCLC study

Study: Interactions between inflammation and changes in gut microbiota may result in colon tumors

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News